Menu
Recruiting NCT07071948

A Single-Center Clinical Study on the Efficacy and Safety of VISOR

No phase Interventional Urolithiasis, Calcium Oxalate Kidney Stone

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Multifunctional Integrated Flexible Ureteroscope.
Who it may be relevant to
Registry conditions: Urolithiasis, Calcium Oxalate, Kidney Stone. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Single-Center Clinical Study on the Efficacy and Safety of Vortex Intelligence Stone Optimized Removal (VISOR)

Overview

Goal of this trial: To test a new tool called VISOR in adults (aged 18-80) with 1-3 cm kidney or ureter stones. We want to see: 1. If it's safe and works well 2. If its built-in features (flushing/suction, pressure control, and stone-breaking/removal) help clear stones better while keeping surgery safe. Main questions: 1. Can the VISOR clear stones successfully (with fragments \<4 mm left) for at least 9 out of every 10 people within 24 hours after surgery? 2. Will serious problems (like severe infections or ureteral injuries) happen to no more than 1 in 20 people (5%)? 3. Can the device keep pressure inside the kidney below 30 mmHg (a safe level) during the entire surgery? What participants will do: Have stone removal surgery using VISOR (breaks and removes stones at the same time). Get a CT scan within 24 hours after surgery to check if stones are cleared. Return 4 weeks (±1 week) after surgery for: An imaging test (CT or ultrasound) A check for any health problems related to the surgery.

Interventions

  • Device Multifunctional Integrated Flexible Ureteroscope
    Investigational ureteroscope with three integrated functions: 1. Real-time pressure control: Continuous renal pelvic pressure monitoring with auto-adjustment of irrigation/aspiration flow to maintain pressure \<30 mmHg (safety threshold) 2. Simultaneous lithotripsy \& fragment removal: Holmium laser lithotripsy (200-365 μm fiber) coordinated with suction through working channel 3. Single-pass stone clearance: Designed to reduce residual fragments requiring secondary procedures Distinguishing f

Primary outcome measures

  • 24-hour stone-free rate after Xinwell Scope lithotripsy [Time frame: within 24 hours postoperatively]
Secondary outcome measures (5)
  • 1-month stone-free rate [Time frame: 28±7 days postoperatively]
  • Operative time [Time frame: During surgery]
  • Intraoperative renal pelvic pressure [Time frame: Continuous monitoring during lithotripsy]
  • Ureteral injury rate [Time frame: During surgery]
  • Postoperative complication rate [Time frame: 24h, 28 ±7 days , 1 month]

Eligibility criteria

Inclusion criteria

  • Patients with upper urinary tract calculi, where the maximum diameter of a single calculus or the cumulative diameter of multiple calculi is 1-3 cm
  • Patients who choose to undergo "flexible ureteroscopic holmium laser lithotripsy"
  • Aged 18-80 years, regardless of gender
  • Subjects without mental illness or language dysfunction, who can understand the details of this study and sign the informed consent form

Exclusion criteria

  • Patients with ureteral stricture or a history of ureteral stricture
  • Patients with a history of open renal and/or ureteral surgery or laparoscopic surgery
  • Fever (body temperature ≥ 38℃) due to urinary tract infection or other reasons within one week before surgery
  • Pregnant women, lactating women, or women who are in the menstrual period
  • ASA classification > Grade 3: patients with severe systemic diseases, heart diseases, pulmonary insufficiency, and failure of important organ functions, etc., who cannot tolerate anesthesia or surgery
  • Patients with anatomical malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney
  • Patients with abnormal coagulation function (e.g., international normalized ratio (INR) > 1.5 or platelet count < 80 × 10⁹/L)
  • Patients with failed sheath placement during surgery

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou

Identifiers

NCT: NCT07071948 · 2025-0324

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗